PIK3CA and breast carcinoma: The authors used BYL719 or AZD8186 compounds described as selective inhibitors of PI3Kα or PI3Kβ, respectively, in mutant PIK3CA MCF-7 and mutant PTEN HCC70 breast cancer cells.